Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug

References

• AGRAWAL, A. K. and SHAPIRO, B. H., 1996, Phenobarbital induction of hepatic CYP2B1 and CYP2B2 : pretranscriptional and post-transcriptional effects of gender, adult age, and phenobarbital dose. Molecular Pharmacology, 49, 523–531.
   PubMedGoogle Scholar
• BRADFORD, M., 1976, A rapid, sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Analytical Biochemistry, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• CHOW, T., ImA0KA, S., HIROI, T. and FUNAE, Y., 1996, Reductive metabolism of halothane by cytochrome P450 isoforms in rats and humans. Research Communications in Molecular Pathology and Pharmacology, 93, 363–374.
   Google Scholar
• FRuz, P., BEHRLE, E., BEAUNE, P., EICHELBAUM, M. and KROEMER, H. K., 1993, Differential expression of drug metabolising enzymes in primary and secondary liver neoplasms-immunochemical characterization of cytochrome-P450 3A and glutathione S-transferase. Histochemistry, 99, 443–451.
   PubMedGoogle Scholar
• GOEPTAR, A. R., KOPPELE, J. M. T., LAMME, E. K., PIQUE, J. M. and VERMEULEN, N. P. E., 1993, Cytochrome P450 2B1 mediated one electron reduction of adriamycin — a study with rat liver microsomes and purified enzymes. Molecular Pharmacology, 44, 1267–1277.
   Google Scholar
• GOKHALE, M. S., BuNroN, T. E., ZURLO, J. and YAGER, J. D., 1997, Cytochrome P450 isoenzyme activities in cultured rat and mouse liver slices. Xenobiotica, 27, 341–355.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1997, Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions, 106, 161–182.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V. and KAMINSKY, L. S., 1982, Purification and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital and beta-naphthoflavone. Biochemistry, 21, 6019–6030.
   PubMed Web of Science ®Google Scholar
• HOCKEL, M., SCHLENGER, K., MrrzE, M., SCHAEFER, U. and VAUPEL, P., 1996, Hypoxia and radiation response in human tumors. Seminars in Radiation Oncology, 6, 3–9.
   PubMed Web of Science ®Google Scholar
• KHAN, S. and O'BitrEN, P. J., 1995, Molecular mechanisms of tirapazamine (SR 4233, WIN 5907) induced toxicity under low oxygen concentrations. British Journal of Cancer, 71, 780–785.
   Google Scholar
• Krvisro, K. T., FRITZ, P., LINDER, A., FRIEDEL, G., BEAUNE, P. and KROEMER, H. K., 1995, Immunochemical localization of cytochrome-P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry and Cell Biology, 103, 25–29.
   PubMedGoogle Scholar
• LEWIS, A. D., WALKER, C., MORECROFT, I., HENDERSON, C. and WOLF, C. R., 1995, Role of human NADPH cytochrome P450 CYP 2B gene family in the metabolism of the anticancer bioreductive drug tirapazamine. Proceedings of the American Association for Cancer Research, 36 Abstract 3581.
   Google Scholar
• McKAY, J. A., MURRAY, G. I., WEAVER, R. J., EWEN, S. W. B., MELVIN, W. T. and BURKE, M. D., 1993, Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut, 34, 1234–1239.
   Google Scholar
• McKEowN, S. R., FRIERY 0. P., MCINTYRE, I. A., HEJMADI, M. V., PATTERSON, L. H. and HIRST, D. G., 1996, Evidence of a therapeutic gain when AQ4N or tirapazamine is combined with radiation. British Journal of Cancer, 74 (suppl. XXVII.), S39–42.
   Google Scholar
• McKEowN, S. R., HEJMADI, M. V., MCINTYRE, I. A., MCALEER . and PATTERSON, L. H., 1995, AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. British Journal of Cancer, 72, 76–81.
   Google Scholar
• MURRAY, G. I., MCFADYEN, M. C. E., MITCHELL, R. T., CHEUNG, Y. L., KERR, A. C. and MELVIN, W. T., 1999, Cytochrome P450 CYP3A in human renal cell cancer. British Journal of Cancer, 79, 1836–1842.
   Google Scholar
• MURRAY, G. I., TAYLOR, M. C., BURKE, M. D. and MELVIN, W. T., 1998, Enhanced expression of cytochrome P450 in stomach cancer. British Journal of Cancer, 77, 1040–1044.
   PubMed Web of Science ®Google Scholar
• MURRAY, G. I., TAYLOR, V. E., McKAY, J. A., WEAVER, R. J., EWEN, S. W. B., MELVIN, W. T. and BURKE, M. D., 1995a, Expression of xenobiotic metabolising enzymes in tumours of the urinary bladder. International Journal of Experimental Pathology, 76, 271–276.
   Google Scholar
• MURRAY, G. I., TAYLOR, V. E., McKAY, J. A., WEAVER, R. J., EWEN, S. W. B., MELVIN, W. T. and BURKE, M. D., 1995b, Immunochemical localisation of drug metabolising enzymes in prostate cancer. Journal of Pathology, 177, 147–152.
   Google Scholar
• MURRAY, G. I., WEAVER, R. J., PATERSON, P. J., EWEN, S. W. B., MELVIN, W. T. and BURKE, M. D., 1993, Expression of xenobiotic metabolising enzymes in breast cancer. Journal of Pathology, 169, 347–353.
   Google Scholar
• MURRAY, M. and REroY, G F., 1990, Selectivity in the inhibition of mammalian cytochromes P450 by chemical agents. Pharmacological Reviews, 42, 85–100.
   PubMed Web of Science ®Google Scholar
• NAKASA, H., KOMIYA, M., OHMORI, S., RucruisA, T., Krucui, M. and KITADA, M., 1993, Charac-terisation of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Molecular Pharmacology, 44, 216–221.
   PubMed Web of Science ®Google Scholar
• Nims, R. W., LUBERT, R. A., Jos, C. R., Mairm, D. W. and THOMAS, P. E., 1993a, Comparative pharmacodynamics of CYP2B induction by phenobarbital in the male and female F344/NCr rat. Biochemical Pharmacology, 45, 521–526.
   PubMed Web of Science ®Google Scholar
• NEVIS, R. W., SINCLAIR, J. F., THOMAS, P. E., JONES, C. R., MELum, D. W., SY1, J.-L. and LUBERT, R. A., 1993b, Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver and in cultured hepatocytes. Clinical Research in Toxicology, 6, 188–196.
   Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrates and inhibitor probes for cytochrome P45 Os: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotka, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PATTERSON, L. H., 1993, Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive drugs. Cancer and Metastasis Reviews, 12, 119–134.
   PubMed Web of Science ®Google Scholar
• PATTERSON, L. H. and RALEIGH, S. M., 1998, Reductive metabolism: its application to prodrug activation. In N. J. Gooderham (ed.), Drug Metabolism: Towards the Next Millennium (Amster-dam: IOS Press), pp. 72–79.
   Google Scholar
• Pows, G. and WINCENTSEN, L., 1980, Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P450. Biochemical Pharmacology, 29, 347–351.
   PubMedGoogle Scholar
• RALEIGH, S. M., MURRAY, M. M., ROBSON, T., GALLAGHER, R., McKEowN, S. and PATTERSON, L. H., 1998b, Involvement of human and murine tumour cytochrome P450 in bioreduction of AQ4N, Annals of Oncology, 9, A515.
   Google Scholar
• RALEIGH, S. M., WANOGHO, E., BURKE, M D., McKEowN, S. R. and PATTERSON, L. H., 1998a, Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. International journal of Radiation Oncology Biology Physics, 42, 763–767.
   PubMed Web of Science ®Google Scholar
• RILEY, R. J., HEMINGWAY, S. A., GRAHAM, M. A. and WORKMAN, P., 1993, Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochemical Pharmacology, 45, 1065–1077.
   PubMed Web of Science ®Google Scholar
• RYAN, D. E., RAMANATHAN, L., LA, S., THOMAS, P. E., HANiu, M., SHIVELY, J. E., LIEBER, L. S. and LEvrN, W., 1985, Characterisation of the major form of rat hepatic microsomal cytochrome P450 induced by isoniazid. journal of Biological Chemistry, 260, 6385–6393.
   PubMed Web of Science ®Google Scholar
• RYAN, D. E., THOMAS, P. E., KORZENIOWSKI, D. and LEvrtv, W., 1979, Separation and characterisation of highly purified forms of liver microsomal cytochrome P450 from rats treated with polychlorinated biphenyls, phenobarbital and 3-methylcholanthrene. journal of Biological Chemistry, 254, 1365–1374.
   PubMed Web of Science ®Google Scholar
• Swm, P. J., BLUNT, J. N., DESNOYERS, R., GILES, Y. and PATTERSON, L. H., 1997, DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemotherapy and Pharmacology, 39, 455–461.
   PubMedGoogle Scholar
• SUGIURA, M., IWASAKI, K. and KATO, R., 1976, Reduction of tertiary amine N-oxides by liver microsomal cytochrome P-450. Molecular Pharmacology, 12, 322–334.
   PubMed Web of Science ®Google Scholar
• SUGIURA, M., IWASAKI, K. and KATO, R., 1977, Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P450. Biochemical Pharmacology, 26, 489–495.
   PubMed Web of Science ®Google Scholar
• SUNDSETH S. S. and WAXIVIAN, D. J., 1992, Sex-dependent expression and clofibrate inducibility of cytochrome P450 4A fatty acid omega-hydroxylases. journal of Biological Chemistry, 267, 3915–3921.
   PubMed Web of Science ®Google Scholar
• WALTON, M. I., WOLF, C. R. and WORKMAN, P., 1992, The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochemical Pharmacology, 44, 251–259.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., THOMPSON, S., SMITH, G., McKim, M., ELCOMBE, C. R. and BURKE, M. D. 1994, A comparative study of constitutive and induced alkoxyresorufin 0-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster. Biochemical Pharmacology, 47, 763–773.
   PubMed Web of Science ®Google Scholar